Dopamine D2-like receptor family (D2-like receptors)

The D2-like dopamine receptor family, comprising the D2, D3, and D4 subtypes, represents a group of G protein-coupled receptors (GPCRs) that primarily signal through the Gi/o pathway to inhibit adenylyl cyclase and reduce intracellular cAMP levels (StatPearls, 2023). These receptors are widely distributed throughout the brain, with high concentrations in the striatum, nucleus accumbens, and limbic system, where they modulate motor control, reward processing, and emotional regulation (UniProt, 2024). In the pituitary gland, D2 receptors are essential for inhibiting the secretion of prolactin (PubMed, 2021). Clinically, the D2-like family is the primary target for antipsychotic medications, which act as antagonists to mitigate the positive symptoms of schizophrenia associated with dopaminergic overactivity (NIH, 2022). Conversely, D2 and D3 receptor agonists are standard treatments for Parkinson's disease and restless legs syndrome to compensate for diminished dopaminergic signaling (IUPHAR, 2023). Despite their therapeutic utility, drugs targeting these receptors often cause significant side effects, such as extrapyramidal motor symptoms and endocrine disturbances, due to their broad physiological influence (StatPearls, 2023). Modern drug development also focuses on partial agonists that can stabilize dopaminergic activity, providing a more nuanced therapeutic effect in mood and psychotic disorders (PubMed, 2022).

Other names

D2-family dopamine receptorsD2-type dopamine receptorsGi-coupled dopamine receptorsD2R family

Drugs targeting the D2-like receptor family primarily act through competitive antagonism, agonism, or partial agonism. Antagonists block D2 receptors to treat psychosis, while agonists stimulate these receptors to treat Parkinson's disease. Partial agonists act as functional stabilizers of dopaminergic tone (StatPearls, 2023; IUPHAR, 2023).